| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-25 | Burrows Scott L | officer | Option exercise | 15,000 | $14.50 | $218K |
| 2026-06-25 | Burrows Scott L | officer | Sale | 5,000 | $87.12 | $436K |
| 2026-06-25 | Burrows Scott L | officer | Sale | 10,000 | $87.14 | $871K |
| 2026-06-23 | Fairmount Funds Management LLC | director | C | 666,680 | — | — |
| 2026-06-23 | Fairmount Funds Management LLC | director | Sale | 4,684,781 | $85.31 | $399.66M |
| 2026-06-23 | Fairmount Funds Management LLC | director | C | 16,667 | — | — |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | director | Sale | 20,000 | $100.00 | $2.00M |
| 2026-06-03 | Sloan Sheldon | officer | Option exercise | 8,333 | $27.46 | $229K |
| 2026-06-03 | Sloan Sheldon | officer | Sale | 8,333 | $75.00 | $625K |
| 2026-05-01 | Burrows Scott L | officer | Option exercise | 12,500 | $14.50 | $181K |
| 2026-05-01 | Sloan Sheldon | officer | Option exercise | 78,333 | $27.46 | $2.15M |
| 2026-05-01 | Turtle Cameron | director, officer | Sale | 5,300 | $69.54 | $369K |
| 2026-05-01 | Turtle Cameron | director, officer | Sale | 3,600 | $70.77 | $255K |
| 2026-05-01 | Turtle Cameron | director, officer | Sale | 1,000 | $71.76 | $72K |
| 2026-05-01 | Turtle Cameron | director, officer | Sale | 3,100 | $73.14 | $227K |
| 2026-05-01 | Turtle Cameron | director, officer | Sale | 1,700 | $74.23 | $126K |
| 2026-05-01 | Turtle Cameron | director, officer | Sale | 300 | $74.96 | $22K |
| 2026-05-01 | Burrows Scott L | officer | Sale | 12,500 | $71.37 | $892K |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 21,306 | $69.53 | $1.48M |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 19,656 | $70.61 | $1.39M |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 8,777 | $71.56 | $628K |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 12,777 | $72.94 | $932K |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 10,358 | $73.74 | $764K |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 5,059 | $74.60 | $377K |
| 2026-05-01 | Sloan Sheldon | officer | Sale | 400 | $75.37 | $30K |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-06-23 | SCHEDULE 13D/A | Fairmount Funds Management LLC | — | 8,835,440 | view → |
| 2022-02-10 | SC | BAKER BROS. ADVISORS LP | — | — | view → |
| 2021-03-19 | SC | BAKER BROS. ADVISORS LP | — | — | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-07-20 | SCHEDULE 13D/A | Crescent Biopharma, Inc. | — | 6,593,385 | view → |
| 2026-07-01 | SCHEDULE 13D/A | ORUKA THERAPEUTICS, INC. ORKA | 19.50% | 14,553,895 | view → |
| 2026-06-23 | SCHEDULE 13D/A | SPYRE THERAPEUTICS, INC. SYRE | — | 8,835,440 | view → |
| 2026-06-23 | SCHEDULE 13D/A | Apogee Therapeutics, Inc. APGE | 9.99% | 6,713,519 | view → |
| 2026-06-09 | SCHEDULE 13D/A | Jade Biosciences, Inc. JBIO | 19.99% | 14,069,494 | view → |
| 2026-05-13 | SCHEDULE 13D/A | Viridian Therapeutics, Inc.\DE VRDN | — | 17,201,800 | view → |
| 2026-01-22 | SCHEDULE | Apogee Therapeutics, Inc. APGE | 9.99% | 6,047,027 | view → |
| 2026-01-22 | SCHEDULE | Cogent Biosciences, Inc. COGT | 9.90% | 16,261,918 | view → |
| 2025-10-14 | SCHEDULE | Apogee Therapeutics, Inc. APGE | 9.99% | 5,776,881 | view → |
| 2025-09-15 | SCHEDULE | Dianthus Therapeutics, Inc. /DE/ DNTH | 9.90% | 4,052,052 | view → |
| 2025-03-10 | SCHEDULE | Oruka Therapeutics, Inc. ORKA | 19.99% | 8,511,824 | view → |
| 2024-04-01 | SC | Dianthus Therapeutics, Inc. /DE/ DNTH | — | — | view → |
| 2024-04-01 | SC | Viridian Therapeutics, Inc.\DE VRDN | — | — | view → |
| 2024-04-01 | SC | Apogee Therapeutics, Inc. APGE | — | — | view → |
| 2024-04-01 | SC | Cogent Biosciences, Inc. COGT | — | — | view → |
| 2023-06-13 | SC | Cogent Biosciences, Inc. COGT | — | — | view → |
| 2021-09-23 | SC | Viridian Therapeutics, Inc.\DE VRDN | — | — | view → |
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →